Quest Diagnostics Inc Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Quest Diagnostics Inc (DGX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $42.97 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-02-26
- Quest Diagnostics Inc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $42.97, a 39.65% increase from fiscal 2024.
- Quest Diagnostics Inc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $30.77, a 14.74% decline from fiscal 2023.
- Quest Diagnostics Inc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $36.09, a 34.66% increase from fiscal 2022.
- Quest Diagnostics Inc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $26.80, a 22.82% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2025-12-31 | $42.97 10-K · filed 2026-02-26 |
| 2024-12-31 | $30.77 10-K · filed 2026-02-26 |
| 2023-12-31 | $36.09 10-K · filed 2026-02-26 |
| 2022-12-31 | $26.80 10-K · filed 2025-02-20 |
| 2021-12-31 | $21.82 10-K · filed 2024-02-22 |
| 2020-12-31 | $17.25 10-K · filed 2023-02-21 |
| 2019-12-31 | $14.30 10-K · filed 2022-02-28 |
| 2018-12-31 | $18.14 10-K · filed 2021-02-22 |
| 2017-12-31 | $15.98 10-K · filed 2020-02-20 |
| 2016-12-31 | $10.35 10-K · filed 2019-02-21 |
| 2015-12-31 | $11.57 10-K · filed 2018-02-23 |
| 2014-12-31 | $10.99 10-K · filed 2017-02-22 |
| 2013-12-31 | $12.64 10-K · filed 2016-02-26 |
| 2012-12-31 | $15.87 10-K · filed 2015-02-24 |
| 2011-12-31 | $18.08 10-K · filed 2014-02-18 |
| 2010-12-31 | $17.60 10-K · filed 2013-02-27 |
| 2009-12-31 | $15.78 10-K · filed 2012-02-16 |
| 2008-12-31 | $11.58 10-K · filed 2011-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LABCORP HOLDINGS INC. (LH) | United States | $25.060B | 22.60 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |